TABLE I.
Baseline Characteristics of the Study Population According to CHA2DS2-VASc Score Before and After PSM
| Variable | Before PSM | After PSM | ||||||
|---|---|---|---|---|---|---|---|---|
| Low risk (n = 351) | Moderate risk (n = 218) | High risk (n = 424) | P value | Low risk (n = 159) | Moderate risk (n = 159) | High risk (n = 159) | P value | |
| Age, mean (SD), y | 61.4 (7.0) | 70.1 (5.3) | 76.9 (6.1) | <.01 | 69.9 (7.0) | 70.0 (5.0) | 70.9 (5.9) | .23 |
| Sex, No. (%) | <.01 | .44 | ||||||
| Male | 234 (66.7) | 117 (53.7) | 117 (27.6) | 81 (50.9) | 84 (52.8) | 73 (45.9) | ||
| Female | 117 (33.3) | 101 (46.3) | 307 (72.4) | 78 (49.1) | 75 (47.2) | 86 (54.1) | ||
| BMI, mean (SD) | 24.5 (2.7) | 24.1 (2.8) | 23.9 (2.8) | .02 | 24.0 (2.7) | 24.2 (2.8) | 24.1 (2.9) | .84 |
| Smoking status, No. (%) | .04 | .67 | ||||||
| Smoker | 45 (12.8) | 36 (16.5) | 83 (19.6) | 27 (17.0) | 25 (15.7) | 31 (19.5) | ||
| Nonsmoker | 306 (87.2) | 182 (83.5) | 341 (80.4) | 132 (83.0) | 134 (84.3) | 128 (80.5) | ||
| Medical history,a No. (%) | ||||||||
| Hypertension | 150 (42.7) | 135 (61.9) | 342 (80.7) | <.01 | 103 (64.8) | 92 (57.9) | 108 (67.9) | .16 |
| Dyslipidemia | 89 (25.4) | 57 (26.1) | 208 (49.1) | <.01 | 52 (32.7) | 43 (27.0) | 60 (37.7) | .13 |
| Diabetes | 36 (10.3) | 31 (14.2) | 111 (26.2) | <.01 | 22 (13.8) | 22 (13.8) | 25 (15.7) | .86 |
| Stroke or TIA | 10 (2.8) | 20 (9.2) | 87 (20.5) | <.01 | 10 (6.3) | 15 (9.4) | 14 (8.8) | .56 |
| Heart failure | 1 (0.3) | 4 (1.8) | 13 (3.1) | <.01 | 1 (0.6) | 1 (0.6) | 4 (2.5) | .38 |
| Vascular disease | 14 (4.0) | 21 (9.6) | 74 (17.5) | <.01 | 14 (8.9) | 7 (4.4) | 18 (11.3) | .08 |
| TOAST category,b No. (%) | ||||||||
| Large artery atherosclerosis | 80 (22.8) | 55 (25.2) | 130 (30.7) | .04 | 39 (24.5) | 39 (24.5) | 53 (33.3) | .13 |
| Small vessel occlusion | 147 (41.9) | 75 (34.4) | 147 (34.7) | .08 | 60 (37.7) | 58 (36.5) | 53 (33.3) | .70 |
| Cardioembolism | 17 (4.8) | 9 (4.1) | 13 (3.1) | .44 | 4 (2.5) | 6 (3.8) | 7 (4.4) | .65 |
| Medications at discharge,c No. (%) | ||||||||
| Antiplatelet agents | 280 (79.8) | 161 (73.9) | 330 (77.8) | .26 | 123 (77.4) | 118 (74.2) | 121 (76.1) | .80 |
| Antihypertension agents | 139 (39.6) | 107 (49.1) | 227 (53.5) | <.01 | 78 (49.1) | 73 (45.9) | 80 (50.3) | .72 |
| Statins | 58 (16.5) | 43 (19.7) | 99 (23.3) | .06 | 30 (18.9) | 33 (20.8) | 34 (21.4) | .85 |
BMI, body mass index; CHA2DS2-VAS, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65-74 years, and female sex; PSM, propensity score matching; TIA, transient ischemic attack; TOAST, Trial of ORG 10172 in Acute Stroke Treatment.
a
Some patients had more than 1 comorbidity.
b
Some data were missing.
c
Some patients were prescribed more than 1 medication at discharge.
P < .05 was considered statistically significant.